131 related articles for article (PubMed ID: 20197571)
1. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma.
Ozgen M; Koca SS; Isik A; Ozercan IH
J Rheumatol; 2010 Mar; 37(3):678-9. PubMed ID: 20197571
[No Abstract] [Full Text] [Related]
2. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
[TBL] [Abstract][Full Text] [Related]
3. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice.
Kimura M; Kawahito Y; Hamaguchi M; Nakamura T; Okamoto M; Matsumoto Y; Endo H; Yamamoto A; Ishino H; Wada M; Omoto A; Tsubouchi Y; Kohno M; Yoshikawa T
Biomed Pharmacother; 2007 May; 61(4):222-8. PubMed ID: 17147981
[TBL] [Abstract][Full Text] [Related]
4. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.
Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K
J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of etanercept in bleomycin-induced experimental scleroderma.
Koca SS; Isik A; Ozercan IH; Ustundag B; Evren B; Metin K
Rheumatology (Oxford); 2008 Feb; 47(2):172-5. PubMed ID: 18174229
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-'susceptible' mouse strains.
Oi M; Yamamoto T; Nishioka K
J Med Dent Sci; 2004 Mar; 51(1):7-17. PubMed ID: 15137460
[TBL] [Abstract][Full Text] [Related]
7. Effect of interferon-gamma on experimental scleroderma induced by bleomycin.
Yamamoto T; Takagawa S; Kuroda M; Nishioka K
Arch Dermatol Res; 2000 Jul; 292(7):362-5. PubMed ID: 10966061
[No Abstract] [Full Text] [Related]
8. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
Clin Immunol; 2002 Jan; 102(1):77-83. PubMed ID: 11781070
[TBL] [Abstract][Full Text] [Related]
9. Animal models of scleroderma.
Lakos G; Takagawa S; Varga J
Methods Mol Med; 2004; 102():377-93. PubMed ID: 15286396
[TBL] [Abstract][Full Text] [Related]
10. Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis.
Ursini F; Grembiale RD; D'Antona L; Gallo E; D'Angelo S; Citraro R; Visca P; Olivieri I; De Sarro G; Perrotti N; Russo E
J Invest Dermatol; 2016 Sep; 136(9):1892-1894. PubMed ID: 27251791
[No Abstract] [Full Text] [Related]
11. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma.
Yamamoto T; Takagawa S; Katayama I; Nishioka K
Clin Immunol; 1999 Jul; 92(1):6-13. PubMed ID: 10413648
[TBL] [Abstract][Full Text] [Related]
12. Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride.
Christner PJ; Artlett CM; Conway RF; Jiménez SA
Arthritis Rheum; 2000 Nov; 43(11):2598-605. PubMed ID: 11083286
[TBL] [Abstract][Full Text] [Related]
13. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts.
Murota H; Hamasaki Y; Nakashima T; Yamamoto K; Katayama I; Matsuyama T
Arthritis Rheum; 2003 Apr; 48(4):1117-25. PubMed ID: 12687556
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the effect of halofuginone on bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
Rheumatology (Oxford); 2002 May; 41(5):594-6. PubMed ID: 12011392
[No Abstract] [Full Text] [Related]
15. Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma.
Kohno S; Endo H; Hashimoto A; Hayashi I; Murakami Y; Kitasato H; Kojima F; Kawai S; Kondo H
Biomed Pharmacother; 2006 Jan; 60(1):18-25. PubMed ID: 16337105
[TBL] [Abstract][Full Text] [Related]
16. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma?
Yamamoto T
Clin Immunol; 2002 Mar; 102(3):209-16. PubMed ID: 11890707
[No Abstract] [Full Text] [Related]
17. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
[TBL] [Abstract][Full Text] [Related]
18. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A
Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective.
Yamamoto T; Nishioka K
Exp Dermatol; 2005 Feb; 14(2):81-95. PubMed ID: 15679577
[TBL] [Abstract][Full Text] [Related]
20. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
Yamamoto T
Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
